ABAmeni Bedoui

Ameni Bedoui

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ameni Bedoui has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Ali Gargouri

    Affiliation Laboratory of Molecular Biotechnology of Eukaryotes, Center of Biotechnology of Sfax, University of Sfax, Sfax, Tunisia

    1 shared publication
  • Ali Gargouri

    Centre de Biotechnologie de Sfax

    1 shared publication
  • Fahmi Smaoui

    Affiliation Laboratory of Microbiology, Research Laboratory for Microorganisms and Human Disease LR03SP03, Habib Bourguiba University-Hospital, Sfax, Tunisia

    1 shared publication
  • Ikram Ben Amor

    Affiliation Regional Center of Blood Transfusion of Sfax-LR19SP05, University of Sfax, Sfax, Tunisia

    1 shared publication
  • Ikram Ben Amor

    Regional Blood Transfusion Center of Sfax (Tunisia) and Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia

    1 shared publication
  • Ikram Dammak

    Laboratory of Haematology, Hedi Chaker Hospital, Sfax, Tunisia and Faculty of Medicine of Sfax, University of Sfax, Sfax, Tunisia

    1 shared publication

Latest Publications

  • Cytoplasmic CD3 Negativity in Early T-Cell Acute Lymphoblastic Leukemia: A Diagnostic Challenge in Flow Cytometry

    by Nour Louati, Imen Frikha, Ikram Dammak, Imen Krichen, Ameni Bedoui, Rania Abdelmaksoud, Moez Mdhaffer, Ikram Ben Amor

  • Open Access

    Genomic characterization and prognostic significance of copy number alterations in Tunisian patients with acute lymphoblastic leukemia

    by Ameni Bedoui, Wajdi Ayadi, Nour Louati, Imen Frikha, Yosra Fakhfakh, Fahmi Smaoui, Ali Gargouri, Ikram Ben Amor, Moez Elloumi, Moez Mdhaffar, et al.

    Acute lymphoblastic leukemia (ALL) is a heterogeneous malignancy characterized by various genomic alterations playing a crucial role in disease classification, prognosis, and response to treatment. However, molecular diagnosis and effective management of this hematological malignancy remain a major challenge, particularly in developing countries, including Tunisia. In this study, we aimed to conduct a detailed analysis of copy number alterations (CNAs) associated with ALL in a cohort of 60 primary samples from Tunisian patients. Using multiplex ligation-dependent probe amplification (MLPA), major genetic lesions, including IKZF1 , CDKN2A/2B , PAX5 , ETV6 , BTG1, and genes located in the PAR1 region, were analyzed and their associations with clinical and laboratory features, as well as survival outcomes, were also evaluated. Our analysis revealed that 70% of patients had deletions and/or amplifications in at least one gene. The most frequently observed deletions were in CDKN2A/2B (33.3%, n = 20), IKZF1 (30%, n = 18), and PAX5 genes (25%, n = 15). BTG1 deletions were significantly associated with female gender, IKZF1 deletions were more frequent in adult patients, in those with elevated white blood cell (WBC) counts, and in cases involving the BCR::ABL1 translocation, while duplications of the PAR1 region were significantly associated with hyperdiploïdy. Regarding treatment response, cases of IKZF1 deletions showed a significant association with poor glucocorticoid response (GC) at day 8 of treatment and positive minimal residual disease (MRD) rates at days 33 and 63, particularly in B-ALL cases. Furthermore, patients with IKZF1 deletions were associated with significantly lower survival rates in both univariate and multivariate analyses compared to those without these deletions. Additionally, the integration of IKZF1 deletion status into risk stratification models revealed markedly different survival outcomes, highlighting its potential interest in developing new stratification algorithms. These results underscore the critical importance of molecular profiling, particularly IKZF1 status, for improving outcomes in ALL patients in Tunisia.

  • Open Access

    Mitochondrial Adaptations Underlying Tetraploidization in Human Cancer, Fungal, and Yeast Models

    by Mohamed Jemaà, Ameni Bedoui, Nihel Ammous, Ali Gargouri, Mohamed Guerfali

    Whole-genome duplication, or tetraploidization, occurs in cells, tissues, or entire organisms. In human cancers, tetraploidization promotes aneuploidy and genomic instability, accelerating tumor progression, metastasis, and drug resistance. These adaptations demand metabolic rewiring, including mitochondrial plasticity. Here, we investigate the relationship between mitochondrial quantity/activity, including the mitochondrial transmembrane potential, the intracellular calcium, and the oxidative stress in diploid versus tetraploid cancer cells (colon, sarcoma, liver) and fungal and yeast models (C. albicans diploid/tetraploid strains; S. cerevisiae haploid/diploid/tetraploid strains). We demonstrate that tetraploid cells, whether from human carcinomas or yeast, exhibit consistently enlarged cell size, elevated mitochondrial content, and heightened metabolic activity compared to diploids. Our findings underscore mitochondrial adaptation as a hallmark of tetraploidization, offering novel therapeutic targets for chromosomally unstable tumors.